CAV2 encodes Caveolin-2, the second member of the caveolin protein family that co-assembles with Caveolin-1 (CAV1) to form functional caveolae at the plasma membrane. Located on chromosome 7q31.1, adjacent to the CAV1 gene, CAV2 is expressed ubiquitously but at lower levels than CAV1. While CAV1 is sufficient for caveolae formation, CAV2 stabilizes and modulates caveolar function, and has distinct signaling roles that complement its partner caveolin[1][2].
The caveolin gene family (CAV1, CAV2, CAV3) arose from a common ancestor through gene duplication, with CAV2 and CAV1 being particularly closely linked—located in the same genomic region and often co-expressed. CAV2's functions are intertwined with CAV1 but also include unique aspects, particularly in cellular trafficking, Golgi function, and specific signaling pathways. In the nervous system, CAV2 contributes to neuronal signaling and has been implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[3][4].
Caveolin-2 shares structural homology with CAV1 but has distinct features:
| Domain | Residues | Function |
|---|---|---|
| N-terminal scaffolding domain | 1-75 | Binds signaling proteins |
| Hydrophobic domain | 76-103 | Membrane insertion |
| C-terminal domain | 104-162 | Dimerization, interactions |
CAV2 (∼18 kDa) differs from CAV1 in:
CAV2 functions primarily as a heterodimer with CAV1:
While requiring CAV1 for caveolae formation, CAV2 has independent functions:
| Function | Description |
|---|---|
| Golgi localization | CAV2 cycles through the Golgi apparatus |
| Vesicular trafficking | Independent of classical caveolae |
| Signaling modulation | Distinct downstream pathways |
CAV2 contributes to caveolae through[5]:
CAV2 organizes distinct signaling complexes:
| Pathway | CAV2 Interaction |
|---|---|
| MAPK/ERK | Modulates downstream signaling |
| PI3K/Akt | Sequesters specific effectors |
| G proteins | Distinct G protein coupling |
CAV2 has unique trafficking properties[6]:
CAV2 is expressed in neurons and glia:
CAV2 contributes to synaptic biology:
CAV2 participates in BBB function:
CAV2 connections to AD include[3:1]:
CAV2 may contribute to PD[4:1]:
CAV2 has prominent roles in cancer biology[7]:
| Feature | CAV1 | CAV2 | CAV3 |
|---|---|---|---|
| Expression | Ubiquitous | Ubiquitous | Muscle-specific |
| Caveolae formation | Yes | No (requires CAV1) | Yes |
| Genomic location | 7q31.1 | 7q31.1 | 3p22.1 |
| Main functions | Signaling hub | Co-regulator | Muscle-specific |
CAV2 expression:
CAV2 is regulated by:
CAV2 offers therapeutic opportunities:
| Approach | Strategy | Potential Use |
|---|---|---|
| Signaling modulators | Target CAV2-associated pathways | Neurodegeneration |
| Delivery vectors | Use caveolae for drug delivery | Brain targeting |
| Gene therapy | Modulate expression | Cancer |
CAV2 interacts with:
| Partner | Interaction | Function |
|---|---|---|
| CAV1 | Heterodimer | Caveolae formation |
| CAV2 | Homodimer | Complex stability |
| Cholesterol | Binding | Membrane organization |
| G proteins | Scaffold | Signal modulation |
| EGFR | Scaffold | Signaling regulation |
Parton RG, del Pozo MA. Caveolae as plasma membrane sensors, protectors and organizers. Nature Reviews Molecular Cell Biology. 2018. ↩︎
Williams TM, Lisanti MP. The caveolin genes: from cell biology to disease. Trends in Cell Biology. 2004. ↩︎
Gaudreault SB, Dea D, Poirier J. Increased caveolin-1 expression in Alzheimer's disease and AD transgenic mouse brain. Journal of Alzheimer's Disease. 2008. ↩︎ ↩︎
Garcia ML, Udem S, Cleveland DW. Caveolin-1 in the pathogenesis of Parkinson's disease. Parkinsonism & Related Disorders. 2009. ↩︎ ↩︎
Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiological Reviews. 2004. ↩︎
Fujimoto T, Kogo H, Nomura R, Une T. Caveolin-2 localizes to the Golgi complex and distinct vesicular structures. Journal of Cell Science. 2000. ↩︎
Krajewska WM, Masłowska I, Czuwara J, Kossykowska M, Rzechonek A, Łuczak J, Iwanicki MP, Szczepanski M, Kwiatkowska E, Stasiak M, Wierus J, Kowalski M, Grygoruk A, Kaczmarczyk P, Kaszuba B, Kozłowski M, Sagan D, Dyduch G, Leśniewska E, Pihowicz P, Rudnicka L, Wojas B, Pawłowski J, Ptaszyński W, Szmajda K, Dyduch W, Grzybowska-Szatkowska L, Habryka I, Duda T, Madej G, Gawrychowski J, Kowalski A, Kowalski J, Lipiński P, Małek B, Ostrowska H, Paradowska A, Ptak A, Rogalski P, Słomiany M, Stachoń M, Waśko G, Wiśniewski P, Zbytek B, Zbyryt M, Zegarski W, Ziomek M, Ziółkowski P, Zubik P, Żebracka J, Żygadło M, Żywko J, Adamiec R, Błazej R, Bogucka-Kocka A, Borawska J, Brzeziński J, Burchacka E, Chamienia D, Chojnacki J, Chosia M, Cwynar M, Czajka M, Czerepak M, Dąbrowska M, Dobrowolska A, Domańska I, Drąg J, Drąg M, Drąg Z, Drelich G, Dymek P, Dzierżykray-Rogalska R, Fal V, Filewska M, Frank J, Gadzalski M, Gąsior J, Gil J, Gisterek I, Giza A, Gładysz E, Gnysz J, Godlewski D, Gogacz M, Gogacz E, Gondek A, Gorczyński A, Grabiec J, Grela M, Grzybowska E, Gutowski J, Hajto B, Jeleń M, Jelski W, Jordan J, Jóźwiak J, Kalinka-Warzocha E, Kamiński M, Kapturska K, Karbownik M, Karcz G, Kędra B, Kijowski J, Kisiel R, Klonarz S, Kobierska G, Kołodziejski L, Komorowski J, Konopka B, Koprowski A, Korlaga D, Kowalczys K, Kowalczyk M, Krajewska M. Caveolin-2 in cancer and metastasis. Advances in Cancer Research. 2008. ↩︎